MassBio Elects MacKay Chairman, Welcomes 3 New Board Members Arnstein, Hoyes and Lucchino to Join Board
Arnstein, Hoyes and Lucchino to join board
CAMBRIDGE, MA (March 27, 2012) – MassBio members today elected a new chairman and three new board members at the 2012 MassBio Annual Meeting.
Geoff MacKay, president and CEO of Canton-based regenerative medicine company Organogenesis Inc., was elected board chairman for a two-year term. MacKay has served as president and CEO of Organogenesis since 2003 and provides significant global, commercial experience spanning the pharmaceutical and biotechnology sectors. He has been specifically involved in the emerging field of regenerative medicine for the last decade.
“Geoff has long been a champion and an advocate for the biotechnology industry in Massachusetts and we look forward to his vision for the future of the industry association,” Robert K. Coughlin, President & CEO of MassBio.
Joining the board this year are Caren Arnstein, senior vice president and Head of Communications for Genzyme, James Hoyes, President of EMD Serono, Inc., and David L. Lucchino, CEO of Semprus BioSciences.
“We are honored to add three such prestigious names and organizations to our Board of Directors, with each reinforcing a piece MassBio’s commitment to the industry here in Massachusetts,” Coughlin said. “Caren has worked in the industry in Massachusetts for nearly two decades years and represents a true homegrown success story in Genzyme. Jim’s experience over his career—especially his expertise in industry partnerships—bring us strength in one of the hottest topics in industry. And David’s tenure as co-founder of an innovative emerging growth company spun out of MIT represents the Greater Boston area’s commitment to cutting edge medical technology innovation. With these elections we emphasize our mission to be a voice for the totality of the industry in Massachusetts.”
The 2012-2013 members of the MassBio Executive Committee are:
Chair Geoff MacKay, Organogenesis Inc.
Vice Chair Glenn Batchelder, Civitas Therapeutics
Treasurer Michael O'Hara, Deloitte
Clerk Abbie Celniker, Eleven Biotherapeutics
Past Chair Geoffrey Cox, Red Sky Partners
The 2012-2013 members of the MassBio Board of Directors are:
Caren Arnstein, Genzyme
Mark Bamforth, Gallus Biopharmaceuticals
Margaret Chu-Moyer, Amgen
Jeffrey Elton, Accenture
Scott Gillis, Onsite Therapeutics
Steven Gilman, Cubist Pharmaceuticals
Jose Carlos Gutierrez-Ramos, Pfizer
John Harrington, sanofi
John Hennessy, AstraZeneca R&D Boston
James Hoyes, EMD Serono
Peter Isakson, Abbott Laboratories
Edwin Kania, Flagship Ventures
Laurie Bartlett Keating, Millennium: The Takeda Oncology Company
Mark Leuchtenberger, Rib-X Pharmaceuticals
David Lucchino, Semprus BioSciences
Deanna Petersen, Shire Pharmaceuticals
David Reif, AstraZeneca R&D Boston
Steven Richter, Microtest Laboratories
Amit Sachdev, Vertex Pharmaceuticals
Frank Thomas, AMAG Pharmaceuticals
Kathleen Tregoning, Biogen Idec
Charles Wilson, Novartis
Lawrence Wittenberg, Goodwin Procter
Bill McDermott, McDermott, Quilty & Miller
Robert Gottlieb, RMG Associates